Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Ewing’s sarcoma, a rare pediatric cancer, by The U.S. Food and Drug Administration (FDA), the company announced today.

“We are delighted to announce receipt of our third RPDD from the FDA, which underscores Cellectar’s commitment to rare pediatric cancers,” Cellectar Biosciences Chief Medical Officer John Friend said in a statement. “This designation, combined with our receipt of FDA Orphan Drug Designation for Ewing’s sarcoma last month, will help support our efforts to optimize the drug development path in this indication and, if successful, enable this new therapeutic candidate is made available to patients as rapidly as possible.”

The company received an RPDD for its phospholipid drug conjugate, CLR 131, for the treatment of neuroblastoma in May.